LBPMedicine(SH:688393) Xin Lang Zheng Quan·2025-10-20 02:05Core Viewpoint - Anbiping's stock price has shown significant volatility in 2023, with a year-to-date increase of 48.81%, but recent declines in the short term indicate potential challenges ahead [2]. Company Overview - Anbiping, established on July 6, 2005, and listed on August 20, 2020, is located in Guangzhou, Guangdong Province. The company specializes in the research, production, and sales of in vitro diagnostic reagents and instruments [2]. - The company's revenue composition includes 79.72% from self-produced products, 13.11% from purchased products, 5.90% from service income, and 1.27% from other sources [2]. Financial Performance - For the first half of 2025, Anbiping reported operating revenue of 159 million yuan, a year-on-year decrease of 30.11%. The net profit attributable to the parent company was -12.5 million yuan, reflecting a year-on-year decline of 176.38% [2]. - Cumulatively, Anbiping has distributed 87.8 million yuan in dividends since its A-share listing, with 36.5 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, Anbiping had 9,221 shareholders, a decrease of 10.55% from the previous period. The average number of circulating shares per person increased by 11.80% to 10,147 shares [2]. - Among the top ten circulating shareholders, Changcheng Consumption Value Mixed A (200006) is the eighth largest, holding 850,000 shares as a new shareholder [3]. Market Activity - On October 20, Anbiping's stock price rose by 2.03% to 25.61 yuan per share, with a trading volume of 4.9146 million yuan and a turnover rate of 0.21%. The total market capitalization stood at 2.396 billion yuan [1]. - Despite the recent price increase, there has been a net outflow of 276,700 yuan in principal funds, with no large purchases recorded [1].